Cell & Gene Therapies

This life science panel focuses on cell and gene therapy, a cutting-edge field
revolutionizing modern medicine where we delve into the forefront of medical
innovation. The panel will explore the transformative potential of manipulating cellular
and genetic mechanisms to treat diseases, paving the way for personalized medicine
and improved patient outcomes. From curing genetic disorders to enhancing cancer
treatments, the potential of these therapies to redefine human health is immense. Our
esteemed panelists, experts at the forefront of research and clinical application, will
share insights, challenges, and breakthroughs in this rapidly evolving discipline.
Together, let's unravel the mysteries and promises of cell and gene therapy, shaping the
future of healthcare for generations to come. Join us as we navigate the promising
landscape of regenerative therapies and discuss their ethical, regulatory, and scientific
implications.

MODERATOR:

Jeffrey N. Hausfeld M.D., M.B.A., F.A.C.S.
Chairman of the Board of Directors and Chief Medical Officer– BioFactura Inc.
Jeffrey Hausfeld, M.D., M.B.A., F.A.C.S., has served on the national board and committees of specialty medical societies since he began his practice in Otolaryngology/Facial Plastic Surgery in 1982. He is an Associate Clinical Professor of Surgery at George Washington University School of Health Sciences and an alumnus of the Yale University School of Medicine. Dr. Hausfeld is widely published in the medical literature, is the pioneer of innovative laser surgery techniques, is the author of a lay oriented medical book, and has appeared on numerous local and national television and radio shows as a medical expert. Read full profile…

PANEL:

Jeff Galvin
CEO and Founder, American Gene Technologies®
Jeff Galvin is the CEO and Founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Read full profile…

Jeffrey Hung, Ph.D
Founder and CEO, DiscerNMR
Jeffrey Hung, Ph.D, is a Subject Matter Expert (SME) for Cell and Gene Therapy and CEO of DiscerNMR. Dr. Hung was the General Manager and Chief Commercial Officer of Vigene Biosciences, a leading gene delivery company that was acquired by CRL in July 2021 for $302 Million. As the General Manager of GMP Business, Dr. Hung orchestrated Vigene Biosciences’s acquisition of Omnia Biologics in 2016, a CMO specializing on GMP manufacturing of viruses. Read full profile…

Murat Kalayoglu, MD, PhD
Co-founder and Director, Cartesian Therapeutics
Dr. Kalayoglu is Co-Founder of Cartesian and served as the company’s President and CEO prior to its merger with Selecta in November 2023. Prior to Cartesian, Dr. Kalayoglu was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan (NYSE:AGN). Dr. Kalayoglu was also co-founder and COO of HealthHonors Corporation, which he led from concept to commercialization, followed by a successful sale to Healthways (NASDAQ:HWAY). Read full profile…